Published in J Oncol on June 29, 2010
Retracted Advanced Glycation End-Products Enhance Lung Cancer Cell Invasion and Migration. Int J Mol Sci (2016) 1.38
Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro. PLoS One (2014) 0.85
Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes Metab Syndr Obes (2015) 0.79
Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res (2012) 0.79
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol (2015) 0.78
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases. Diagnostics (Basel) (2016) 0.75
Obesity and cancer: at the crossroads of cellular metabolism and proliferation. Surg Obes Relat Dis (2014) 0.75
DNA-aptamers raised against AGEs as a blocker of various aging-related disorders. Glycoconj J (2016) 0.75
Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncol Lett (2017) 0.75
Glyceraldehyde-Derived Advanced Glycation End Products Accumulate Faster Than N(ε)-(Carboxymethyl) Lysine. Ann Dermatol (2017) 0.75
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinases. J Biol Chem (1999) 12.08
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 5.49
Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03
Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J (1999) 4.85
TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res (2005) 4.24
Diabetes and advanced glycation endproducts. J Intern Med (2002) 3.38
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev (2006) 3.14
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem (1999) 3.12
Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol (2001) 2.28
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des (2005) 2.06
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol (2002) 1.82
Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res (2004) 1.66
Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. J Biol Chem (2002) 1.47
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol (2005) 1.36
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun (2002) 1.36
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem (2002) 1.27
Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep (2003) 1.26
Sustained production of H(2)O(2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway. J Biol Chem (2002) 1.23
TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med (2006) 1.10
Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol (2004) 1.09
Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol (2000) 1.09
Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer (2003) 1.09
De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim Biophys Acta (2007) 1.06
Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol (2005) 1.06
Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis (2009) 1.01
Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen (2006) 0.99
Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med (2001) 0.99
Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res (2004) 0.98
Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology (2002) 0.98
Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology (2005) 0.91
Advanced glycation end products: detection and reversal. Methods Enzymol (1999) 0.89
Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract (2007) 0.86
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett (2006) 0.83
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging (2011) 2.00
Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol (2002) 1.86
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells (2008) 1.72
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes (2006) 1.43
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun (2002) 1.36
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J (2002) 1.32
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem (2006) 1.30
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol (2004) 1.29
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem (2002) 1.27
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism (2006) 1.26
Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications (2002) 1.26
Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes (2006) 1.22
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun (2009) 1.19
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci (2005) 1.19
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int (2004) 1.19
Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun (2002) 1.19
Role of AGEs in diabetic nephropathy. Curr Pharm Des (2008) 1.14
Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract (2006) 1.13
TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med (2006) 1.10
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res (2011) 1.10
Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol (2004) 1.09
Strong association between serum hepatocyte growth factor and metabolic syndrome. J Clin Endocrinol Metab (2005) 1.08
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res (2007) 1.05
Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res (2006) 1.05
Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther (2010) 1.04
Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin Chem (2006) 1.03
Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism (2011) 1.02
Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res (2005) 1.01
Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen (2006) 0.99
Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol (2013) 0.99
Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev (2009) 0.98
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol (2004) 0.97
Glycation--a sweet tempter for neuronal death. Brain Res Brain Res Rev (2003) 0.97
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int (2003) 0.97
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett (2005) 0.97
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev (2008) 0.97
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res (2007) 0.97
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol Res (2009) 0.97
Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des (2014) 0.96
Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res (2003) 0.96
Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb (2011) 0.96
Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett (2002) 0.96
Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res (2005) 0.96
Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med (2006) 0.96
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res (2007) 0.95
Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev (2009) 0.95
A new vasculitis activity score for predicting death in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis patients. Am J Nephrol (2011) 0.95
Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) (2011) 0.94
Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant (2008) 0.93
Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol (2008) 0.92
Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care (2012) 0.91
Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol (2004) 0.91
Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun (2002) 0.91
Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res (2010) 0.90
Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med (2002) 0.90
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism (2009) 0.89
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism (2012) 0.89
Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther (2011) 0.89
Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res (2003) 0.89
DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes (2013) 0.89
Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy. J Biol Chem (2004) 0.89
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin Cardiol (2011) 0.88
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diab Vasc Dis Res (2013) 0.88
Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury. Pharmacol Res (2011) 0.87
MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells. World J Gastroenterol (2010) 0.87
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev (2013) 0.87
Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells. Am J Pathol (2009) 0.87
Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton) (2007) 0.86
Involvement of membrane type 1-matrix metalloproteinase (MT1-MMP) in RAGE activation signaling pathways. J Cell Physiol (2011) 0.86
Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun (2010) 0.86
Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod (2011) 0.86
Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol (2012) 0.86
Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract (2007) 0.86
Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun (2004) 0.86
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes. Microvasc Res (2007) 0.86
PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvasc Res (2012) 0.86
Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation. Protein Pept Lett (2008) 0.85
Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin Biochem (2012) 0.85
Macrophage migration inhibitory factor ameliorates UV-induced photokeratitis in mice. Exp Eye Res (2008) 0.85
Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol (2014) 0.85
Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol Med (2002) 0.85
Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT. J Clin Endocrinol Metab (2015) 0.84
Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic β-cells. J Hepatobiliary Pancreat Sci (2013) 0.84
Advanced glycation end products increase permeability of brain microvascular endothelial cells through reactive oxygen species-induced vascular endothelial growth factor expression. J Stroke Cerebrovasc Dis (2011) 0.84
Proteasome inhibition induces selective motor neuron death in organotypic slice cultures. J Neurosci Res (2005) 0.84
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun (2009) 0.84
Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun (2010) 0.84